Novo Nordisk’s (NVO) etavopivat was granted FDA orphan designation for treatment of thalassemias, according to a post on the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- NVO Lawsuit Alert! Class Action Lawsuit Against Novo Nordisk A/S
- Eli Lilly launches weight-loss drug Mounjaro in India, Reuters says
- Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
- Eli Lilly (LLY) Leads India’s Weight-Loss Drug Race with Mounjaro
- Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching Barrier